Oncology
ASCO 2026: Pluvicto shows consistency, with Dr Fred Saad
In a conversation at ASCO 2026, Dr Fred Saad of the University of Montreal shared some insights from a subgroup analysis of Pluvicto
Oncology
ASCO 2026: All about DNA damage response, with Luke Piggot
Luke Piggot, a principal scientist at Debiopharm, shares some recent data and news about the company's work in DNA damage repair inhibitors.
Patients
ASCO 2026: New hope in AL amyloidosis, with Dr Hans Lee
A phase 1/2 trial in AL amyloidosis saw 100% of patients obtaining at least a very good partial response with 90% obtaining a complete response.
Sales & Marketing
Digital
Market Access
Editor's Picks
Editor's Picks
